The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Statistical Considerations in the Intent-to-Treat Principle
Abstract
This paper describes some of the statistical considerations in the intent-to-treat design and analysis of clinical trials. The pivotal property of a clinical trial is the assignment of treatments to patients at random. Randomization alone, however, is not sufficient to provide an unbiased comparison of therapies. An additional requirement is that the set of patients contributing to an analysis provides an unbiased assessment of treatment effects, or that any missing data are ignorable. A sufficient condition to provide an unbiased comparison is to obtain complete data on all randomized subjects. This can be achieved by an intent-to-treat design wherein all patients are followed until death or the end of the trial, or until the outcome event is reached in a time-to-event trial, irrespective of whether the patient is still receiving or complying with the assigned treatment. The properties of this strategy are contrasted with those of an efficacy subset analysis in which patients and observable patient data are excluded from the analysis on the basis of information obtained postrandomization. I describe the potential bias that can be introduced by such postrandomization exclusions and the pursuant effects on type I error probabilities. Especially in a large study, the inflation in type I error probability can be severe, 0.50 or higher, even when the null hypothesis is true. Standard statistical methods for the analysis of censored or incomplete observations all require the assumption of missing at random to some degree, and none of these methods adjust for the potential bias introduced by post hoc subset selection. Nor is such adjustment possible unless one posits a model that relates the missing observations to other observed information for each subject-models that are inherently untestable. Further, the subset selection bias is confounded with the subset-specific treatment effect, and the two components are not identifiable without additional untestable assumptions. Methods for sensitivity analysis to assess the impact of bias in the efficacy subset analysis are described. It is generally believed that the efficacy subset analysis has greater power than the intent-to-treat analysis. However, even when the efficacy subset analysis is assumed to be unbiased, or have a true type I error probability equal to the desired level alpha, situations are described where the intent-to-treat analysis in fact has greater power than the efficacy subset analysis. The intent-to-treat design, wherein all possible patients continue to be followed, is especially powerful when an effective treatment arrests progression of disease during its administration. Thus, a patient benefits long after the patient becomes noncompliant or the treatment is terminated. In such cases, a landmark analysis using the observations from the last patient evaluation is likely to prove more powerful than life-table or longitudinal analyses. Examples are described.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the analyses for Aims 1 and 2 described below, all randomized participants will be included in intent-to-treat analyses [50], as the aims are concerned with the impact of the intervention on outcomes regardless of study completion status.”
From Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer (2020) · cites this paper as [50]
In the citing paper
“For the intervention study: Statistical procedures are run both by protocol (that is: only available data observed at any time point from every participant are considered) and by intent-to-treat (ITT) with the last intervention carried forward (LOCF) (152).”
In the citing paper
“A limitation of this approach is the introduction of potential subset selection bias that cannot be distinguished from the treatment effect35.”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550 · cited 2×
“For analyses of incomplete longitudinal data using GEE, Rotnitzky and Wipij [60] describe methods to assess the possible bias in the coefficient estimates introduced by missing data.”
MethodStatistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
A test of missing completely at random for multivariate data with missing values
Little, R. J. A. (1988) · Journal of the American Statistical Association · doi:10.1080/01621459.1988.10478722 · Cited by 8,963 · cited 2×
“" Little [35] [36] [37] describes a family of pattern mixture models wherein, by conditioning on the pattern of missing observations, it is assumed that the mechanisms leading to missing data are accounted for and any bias eliminated.”
MethodRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923 · cited 1×
“These include multivariate rank tests [32], random effects models for repeated measures [33], and analysis of longitudinal data using generalized estimating equations (GEE) [34].”
MethodPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Multiple Imputation for Nonresponse in Surveys.
Lynn, P., & Rubin, D. B. (1988) · The Statistician · doi:10.2307/2348774 · Cited by 2,329
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Fundamentals of Clinical Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · doi:10.1007/978-3-319-18539-2 · Cited by 2,237
Research works printed but not linked: 4
- Tsiatis, 1990, Analysis and interpretation of trial results, J Acquir Immune Defic Syndr, 3, S120
- Food and Drug Administration. International Conference on Harmonization: Guidance on general considerations for clinical trials. Federal Register 1997; 62(242):66113–66119.
- Food and Drug Administration. International Conference on Harmonization: Guidance on statistical principles for clinical trials. Federal Register 1998; 63(179):49583–49598.
- Heyting, 1993, Author's Reply, Stat Med, 12, 2248
Cited by
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
(2008) · Cited by 3,790
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030656 · Cited by 2,043
Metadata
- Authors
- Lachin, J. M.
- Affiliations
- George Washington University (US)
- Corresponding author
- Lachin, John M.
- ORCID
- Lachin, John M.
- Venue
- Controlled Clinical Trials
- Publisher
- Elsevier BV
- Published
- 2000-06
- Volume
- 21
- Issue
- 3
- Pages
- 167-189
- ISSN
- 0197-2456 (ISSN-L)
- OpenAlex
- W1996932065
- Cited by
- 652
- References
- 75
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 19 · 2023: 16 · 2022: 21 · 2021: 21 · 2020: 24 · 2019: 25 · 2018: 22 · 2017: 29 · 2016: 19 · 2015: 38 · 2014: 44 · 2013: 34 · 2012: 43
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Controlled Clinical Trials (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods and Bayesian Inference
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- intention-to-treat analysis, type I error inflation, missing at random, treatment effect estimation, statistical power, landmark analysis, time-to-event data, censored observations, sensitivity analysis, treatment non-adherence, randomization bias
- MeSH terms
- Clinical Trials as Topic, Data Interpretation, Statistical, Probability, Models, Statistical, Bias, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statistical Considerations in the Intent-to-Treat Principle. https://app.cochat.ai/papers/10.1016/s0197-2456(00)00046-5
- The paper
- Lachin, J. M. (2000). Statistical Considerations in the Intent-to-Treat Principle. Controlled Clinical Trials. https://doi.org/10.1016/s0197-2456(00)00046-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.